

Index

- Abbott, F 321
- active pharmaceutical ingredients
(APIs) 115, 126–32
see also trademarks in the
pharmaceutical sector, EU
- advertising
nutrition and health claims 150–52
and packaging and labelling 29–30,
97–8
and trademarks 58–61, 62, 63, 188–9
see also brands; labelling; trademarks
- Agdomar, M 288–9, 291, 292
- alcohol and HFSS (high in fat, salt and
sugar), food packaging
standardization requirements
24–6, 29, 30
- Alemanno, A 1–12, 15–42, 61, 62, 75,
83, 84, 89, 92, 93, 104, 208, 270,
272, 273, 274, 326
- Alexander, D 319–20, 330
- Ali, A 230
- Alsop, R 101
- Anderson, S 60
- appellations of origin 286–7, 293–5
see also geographical indications
- arbitration in investment disputes *see*
under investment disputes,
pharmaceutical patents and
health-related goods
- Atkinson, N 318, 322, 325
- Australia
Australia: The Healthiest Country by
2020 22
freedom of speech 80–81
Hong Kong–Australia BIT, tobacco
packaging measures 220–22,
223, 224–6, 228–30
Patent Office ‘expedited
examination’ system 311
pharmaceutical trademarks *see*
trademarks in the
pharmaceutical sector, EU,
Australian regulatory
requirements comparison
plain packaging of tobacco products,
and WTO challenge *see* plain
packaging of tobacco products,
Australia, and WTO challenge
plain tobacco packaging 1, 3, 19, 20,
22, 41, 49, 61, 215–16, 217, 218
regulatory agency for medical drugs
and devices 27–8
Tobacco Plain Packaging Act 20, 23,
56, 80–81, 136, 207, 208–9,
214–15
Tobacco Plain Packaging Act, Sri
Lanka comparison 189–95
Trade Marks Act 48, 49, 50, 59, 196
- Australia, legal cases
APLA v Legal Services 81
Australian Capital Television Pty v
Commonwealth 80
British American Tobacco
Australasia v Commonwealth of
Australia 81, 218, 228
Campomar Sociedad Limitada v Nike
International 50
The Grain Pool of Western Australia v
The Commonwealth 193–4
JT International v Commonwealth 3,
49, 50, 59, 81, 189, 190, 192,
193–5, 205, 207, 218, 228
Lake Shore and MSR v Kurtz 191
Lange v Australian Broadcasting
Corporation 80
Monis v R; Droudis v R 81
Steers v Rogers 193
Aylwin, N 285

- Bagley, M 315
 Baldwin, R 30, 32
 banned descriptors, renewal of
 trademarks containing 51–2, 60
 bans on brand extension medicines
 (umbrella brands) 133–5
 Bar-Gill, O 31
 Barendt, E 94
 Bartley, T 257
 Barton, J 235
 Bauer, J 301
 Beebe, B 102
 behavioural science and market
 manipulation, certification marks
 for public health 271–2
 behavioural sciences, plain packaging
 and other standardization
 requirements 15–42
 advertising, reducing effect of 29–30
 alcohol and HFSS (high in fat, salt
 and sugar) food packaging 24–6,
 29, 30
 autonomy concerns 18, 40
 citizens' choices, effects on 17–18,
 34–6, 40–41
 Codex Guidelines on Nutrition
 Labelling 27
 consumption control policies 39–42
 effectiveness critique 37–9
 fundamental rights and freedom of
 choice 35–6
 generic packaging history 21–2
 incentives and consumption control
 40, 41
 legitimacy critique 35–6
 mandated disclosure limitations 34,
 40–41
 moral critique 36–7
 nudge interventions, effects of 30–32,
 35–6, 37–9, 40, 41–2
 pharmaceuticals 27–8
 plain packaging semantics 19–20
 plain packaging and tobacco control
 strategies 20–21
 political acceptability 34–5
 promises and pitfalls 34–9
 rationale of package standardization
 28–30
 'regulatory chill' effect 41
 standardization requirements and IP
 regime conflicts 16–17, 41, 42
 tobacco products, increasing
 noticeability and effectiveness of
 health warnings 29
 tobacco products, tar, nicotine and
 carbon monoxide (TNCO)
 yields, removal of 32–3, 35, 40
 trade dress protection 15–16
 'wear-off' effect, risk of 37
 Beier, F-K 309, 320, 324
 Belgium, tobacco plain packaging 23
 Ben-Shahar, O 40, 41, 271, 275
 Bently, L 331
 Bernitz, U 45
 bilateral trade agreements 220–22, 223,
 224–6, 228–30, 321
 see also Free Trade Agreements
 (FTAs) and TRIPS
 Biondi, A 92
 Black, J 291
 Blackaby, N 236
 Blakeney, M 285
 Blanco-Marquizo, A 215
 Block, J 266
 Blum, J 2, 28, 43, 44, 58, 59, 60, 112–37
 Blum, R 320
 Bodenhansen, G 52, 53
 Bohmricj, R 287
 Bonadio, E 1–12, 16, 20, 24, 30, 43–68,
 75, 87, 113, 156, 170, 202, 228,
 274, 305–32
 Bosland, J 55
 Bovens, L 31, 33, 37
 Bowen, S 289, 300
 Brain, R 302, 303
 Braithwaite, J 269
 brands
 brand image and package design as
 expressive activities 95–6
 brand loyalty and cultural
 considerations 99, 100–101
 brand-specific nutrition and health
 claims 154–5
 negative rights, to prevent
 exploitation of 44–6, 50

- pharmaceutical trademark
 - registration and brand protection 112–13, 114–15
- umbrella brands (bans on brand extension medicines) 133–5
 - see also* advertising; labelling; trademarks
- Breheny, S 209
- Broude, T 31, 285
- Brügemeier, G 83
- Bubb, R 34, 41
- Burgess, A 38
- Burrell, R 206
- Büthe, T 257

- Cafaggi, F 268
- Calboli, I 283–304
- Callmann, R 191
- Calo, R 272, 273
- calorie information, certification marks for public health 266–7, 276–9
- Cameron, J 81, 95
- Canada
 - Canadian Medical Association (CMA) on tobacco packaging 21–2
 - Cécilia Létourneau v JTI Macdonald* 179
 - Ford v Attorney-General of Quebec* 95
 - freedom of expression 81
 - Regulations Amending the Food and Drug Regulations 135
 - tobacco advertising 179
 - Tobacco Products Control Act 22, 81
 - umbrella branding in pharmaceuticals 134
- Carpenter, M 87
- Carreño, I 7, 138–59, 326
- certification marks for public health 257–82
 - administrative costs 264–5
 - behavioural science and market manipulation 271–2
 - calorie information 266–7, 276–9
 - certification marks on food, use and impact 258–9
 - consumer awareness issues 264, 265, 269–70, 274–5
 - and consumer choice 270–75
 - consumer purchasing behaviour contradictions 274, 276
 - credence attributes (verification of hidden qualities of a product) 262, 269–70
 - cross-border standards 265, 266, 269
 - definition of certification marks 260
 - facilitation maximization 273–4
 - fair trade certification mark 266
 - geographical indications 261
 - Global Partnership for Safe and Sustainable Agriculture (Global-GAP) 269
 - global public–private partnership (PPP) 257–8
 - global value networks (GVNs) 257–8, 265–70
 - health policy and nudge concept 272, 273–4
 - health-related food products 263
 - label ‘fatigue’ concerns 277–8
 - limitations 263
 - marijuana tracking through supply chain 267
 - market manipulation concerns 259–60, 271–2, 275, 279–81
 - ‘natural’ labels on food products 260
 - notice-based forms of regulation (mandatory disclosure) 258, 269–70, 272
 - nudge concept 271–4
 - ‘organic’ labelling 260, 264, 267, 274–5, 279–81
 - population sub-groups, differing effects on 278–9
 - price factors in consumer choice 277
 - private non-profit organizations and NGOs, involvement of 268–9
 - products liability law 271
 - public health impact 275–81
 - public institution initiatives 266–7
 - supply chain management 267
 - tracermark suggestion 281
 - trademark law and certification marks 259–65

- trademarks and exaggerated marketing claims 259–60
- trademark's signalling function 259, 275
- Chandler, C 42
- Chandon, P 277, 278
- Chen, J 264
- Chen, L 29
- Chile, Food Health Regulation and HFSS warnings 26
- China, patent applications related to unhealthy food 313–14
- Chon, M 257–82
- Christie, A 265
- citizens choices *see* consumers
- Cochoy, Franck 5
- Codex Guidelines on Nutrition Labelling 27
- Collishaw, N 52–3
- commercial communication as trademark 94–7, 144, 148–9, 157–8
- compensation levels, pharmaceutical investment disputes 247
- competence and free movement focus, fundamental rights and trademarks 79–80
- competition
 - distinguishing products from competitors, concerns about 59–60
 - unfair competition as complex and fluctuating 98–9
- compound medicines 127
 - see also* trademarks in the pharmaceutical sector, EU
- compulsory licences, and expropriation of pharmaceutical patents 240
- confidentiality in investment dispute arbitral process 236
- confusion likelihood assessment, trademarks in the pharmaceutical sector, EU 119–20, 123, 124, 126–7, 130
- Conly, S 36
- Connolly, G 29
- Conrad, A 299
- constitutionalization of IP law
 - consideration 85–6
- consumers
 - choices, and plain packaging and other standardization requirements 17–18, 34–6, 40–41
 - choices, price factors 277
 - consumer awareness issues 115, 117, 118, 119–20, 126–7, 131–2, 133, 264, 265, 269–70, 274–5
 - consumer interest promotion and trademark law 78–9, 89–90, 103–5, 106–8, 110
 - consumer interest and value, capitalizing on, geographical indications (GIs) 291–2
 - consumer protection and trademark law, Sri Lanka 206, 210–11
 - information availability 1–2, 5–6, 288–9, 298–9
- consumption control policies 39–42
 - see also* behavioural sciences, plain packaging and other standardization requirements
- Cook, W 191
- Coombe, R 285, 290
- Cooray, A 199
- copyright protection 62
- Cornides, J 253
- Correa, C 46, 195, 318–19
- Corré, P-Y 143
- costs
 - administrative, certification marks for public health 264–5
 - price factors in consumer choice 277
- costs/benefits analysis, patents as tool to encourage production of healthier food 316, 326, 329
- coupling principle, EU Nutrition and Health Claims Regulation (NHCR) 141
- Coutrelis, N 143, 144
- Cram, I 94
- Cramer, C 265
- credence attributes (verification of hidden qualities of a product) 262, 269–70

- see also* certification marks for public health
 cross-border standards, certification marks for public health 265, 266, 269
 cultural considerations and trademarks 99, 100–102
 Cunningham, R 21, 22
- Daintith, T 35
 Davison, M 3, 47, 48, 49, 51, 52, 53, 55, 56, 57, 61, 63–4, 66, 67, 89, 113, 156, 163–83, 190, 191, 194, 196, 219, 228
 Dean, O 56
 Dechezleprêtre, A 312
 Denmark, fat tax 325–6
 depriving owner of economic benefit, pharmaceutical investment disputes 240, 241–3, 244, 245–6
 Derclaye, E 309, 312, 318, 322, 323, 325, 330–31
 descriptive names 116, 117
see also trademarks in the pharmaceutical sector, EU
 differentiation, patents as tool to encourage production of healthier food 319–21, 322–4
 Dillbary, J 259
 Dinwoodie, G 109
 discrimination versus differentiation, patents as tool to encourage production of healthier food 319–21
 disputes, investment *see* investment disputes, pharmaceutical patents and health-related goods
 distinctiveness, lack of sufficient 115–18
see also trademarks in the pharmaceutical sector, EU
 distinguishing products from competitors, concerns about 59–60
 Dogan, S 206, 259
 Drahos, P 4, 269
 Dratler, J 309
 Draudins, O 55–6
 Dreyfuss, R 75, 102
 Du Plessis, J 200, 201
 Dunlop, S 42
 Dunn, C 302
 Durkin, S 42
 Dusollier, S 87
 Dutfield, G 324
- ‘eat local’ movements 302–3
 Ebbeling, C 301
 economic benefit, depriving owner of, in pharmaceutical investment disputes 240, 241–3, 244, 245–6
 economic value of trademark registrations 51, 62
 EFTA court, *Philip Morris Norway AS/ Staten v/Helse-og omsorgsdepartementet* 92
 Elsmore, M 69–111, 157–8, 206
 Emerton, P 47, 51, 56, 57, 61, 63–4, 67, 178
 environmentally sustainable production, encouraging, geographical indications (GIs) 299, 300
 Eskridge, W 39
 Ethiopia, Sidamo coffee licensing 265
 EU
 Charter of Fundamental Rights 6, 71, 82–3, 84, 91–2, 94–5, 157–8
 colour-coded system for food packaging 27
 Community Trademark (CTM) 118, 142, 156
 Consumer Information Regulation 27
 Directorate General for Health and Food Safety (DG SANCO) 70, 79
 European Food Safety Authority (EFSA) 145, 153, 155
 European Medicine Agency (EMA) 113, 120–21, 122–5
 European Patent Convention (EPC) and TRIPS, patents contrary to ordre public or morality 314, 317, 323, 326–7
 European Union trademark 69–70

- food law and registered trademarks 7
 freedom of expression 80–81, 82, 157–8
 fundamental rights and trademarks
 see fundamental rights and trademarks, tobacco and health, EU
 health warnings on caffeine content in energy drinks 25
 Imperial Tobacco and Altadis merger 58
 ‘non-economic’ based rights 96
 nutrition and health claims *see* nutrition and health claims and EU trademark law
 Office of Harmonization in the Internal Market (OHIM) (Trade Marks and Designs) 73, 113, 114, 117, 120
 Patent Office costs/benefits analysis criterion 316
 Pharmaceuticals Directive 242
 ‘protected designation of origin’ (PDO) and ‘protected geographical indication’ (PGI) 295–6
 smoking prevalence rates 107
 Standing Committee on the Food Chain and Animal Health (SCoFAH) 153
 Tobacco Products Directive 17, 19, 32, 44, 46, 60, 67, 202
 Tobacco Products Directive, and fundamental rights *see* fundamental rights and trademarks, tobacco and health, EU
 Trademark Directive and Regulation 142–3, 200–201
 trademark law, nutrition and health claims *see* nutrition and health claims and EU trademark law
 trademarks and exclusive rights 44–5
 trademarks in the pharmaceutical sector *see* trademarks in the pharmaceutical sector, EU
see also individual countries
- EU, legal cases
Adidas AG and Adidas Benelux v Marca Mode 107
Alcon v OHIM 115, 125
André Rossius and Marc Collard v Belgium 91
Autronic v Switzerland 95
Budijovický Budvar v Anheuser-Busch 59
DEB v Germany 95
Deutsches Weintor 85, 91, 93, 146–7
Ehrmann v Zentrale zur Bekämpfung unlauteren Wettbewerbs 147
Ekabe v OHIM 144
Eli Lilly and Company taste trademark application 118
Germany v Parliament and Council 95, 96, 157
GlaxoSmithKline v OHIM 119
Google France 58–9, 205
GP Pharm 120
Green–Swan Pharmaceuticals 144, 148–9
Gut Springenheide and Tusky 79
Herbert Karner v Troostwijk 95, 157
Hollywood v Souza Cruz 98
Imperial Tobacco 157
Kureha Corp v OHIM 115
Laboratórios Wellcome de Portugal 119
Lloyd Schuhfabrik Meyer v Klijsen Handel 79, 98
L’Oreal v Bellure 59
McNeil v OHIM 119
Martin Y Paz Diffusion SA v David Depuydt 44–5
Mundipharma v OHIM 115, 119
Onco Mouse Harvard 316
Philip Morris Brands v Secretary of State for Health 72, 82, 90, 106, 110
Pillbox 17, 67, 98
Poland v European Parliament 17, 67, 98
Promusicae 85
The Queen v Secretary of State for Health, ex p British American Tobacco 60, 67

- Tobacco Products II* 17, 67
Transgenic Animals/HARVARD 315, 316, 326
Upjohn 316
Wellcome Foundation v OHIM 119
Wyeth Holdings 117
Zambrano 96
- European Convention on Human Rights 83, 84, 92, 94–5, 96, 97, 157, 158
- European Court of Human Rights 6, 82–3, 84
- Anheuser-Busch v Portugal* 88, 158
Barthold v Germany 95
Casado Coca v Spain 95, 157
Demuth v Switzerland 95
 and freedom of expression 157
Hertel v Switzerland 95
Jacobowski v Germany 95
Markt Intern Verlag and Klaus Beermann v Germany 95, 157
Stambuk v Germany 95
- Evans, S 55
- exaggerated marketing claims, and trademarks 259–60
- expropriation claims, investment disputes *see* investment disputes, pharmaceutical patents and health-related goods, expropriation claims
- expropriation clauses, tobacco packaging measures under international investment law 224–9
- fair and equitable treatment (FET)
 investment disputes, pharmaceutical patents and health-related goods 247–50
 tobacco packaging measures under international investment law 226, 229–31
- fair trade certification mark 266
see also certification marks for public health
- Fairley, H 95
- fast-track procedures for patent applications 310–13, 317, 319, 331–2
- fat
 HFSS (high in fat, salt and sugar), food packaging standardization requirements 24–6, 29, 30
 substitute patents 307–8
- fee exemption suggestion, patents and production of healthier food 313, 329
- Feinberg, J 105
- Fennelly, General 96, 101, 106
- Ferejohn, J 39
- Ferris Wayne, G 29
- Fhima, I 86, 88
- Fiser, J 280
- Flitner, M 324
- food
 certification marks for public health *see* certification marks for public health
 food-related patents, and production of healthier food 307–8
 geographical indications (GIs) *see* geographical indications (GIs) and public health
 operators' trademarks, use of, EU Nutrition and Health Claims Regulation (NHCR) 143–4
 packaging, alcohol and HFSS (high in fat, salt and sugar) 24–6, 29, 30
see also health; nutrition headings
- Ford, A 210
- foreign direct investment (FDI) and investment treaties 235
- Fouassier, J 291
- France
 appellations of origin 286–7, 293–5
 tobacco packaging 1, 23
- Frankel, S 45, 47, 56, 89, 174, 176
- Fraser, B 95
- free movement focus, fundamental rights and trademarks, tobacco and health, EU 79–80
- free speech rights 102–3, 205–6
- free trade agreements 252, 321
see also bilateral trade agreements
- free-riders, protection from, geographical indications 291–2

- freedom of choice 35–6
- freedom of expression 80–81, 82, 86–8, 94–5, 103–5, 106, 110, 157–8
- Freeman, B 20
- Freuman, T 302
- Friedland, M 280
- Fromer, J 275
- Fujiye, M 257–82
- fundamental rights
 - compliance, EU Nutrition and Health Claims Regulation (NHCR) 156–8
 - and freedom of choice 35–6
 - Sri Lanka, public health objectives through product labelling regulation 206–9
- fundamental rights and trademarks, tobacco and health, EU 69–111
- brand image and package design as expressive activities 95–6
- brokerage of fundamental rights 71–90
- Charter of Fundamental Rights (Article 11) and freedom of expression 71, 82–3, 84, 91, 94–5
- Charter of Fundamental Rights (Article 35) and right to health 91–2
- compelled speech as corollary of the right to free speech 102–3
- competence and free movement focus 79–80
- constitutionalization of IP law consideration 85–6
- consumer interest promotion and trademark law 78–9, 89–90, 103–5, 106–8, 110
- cultural considerations and brand loyalty 99, 100–101
- cultural currency and ‘self-expression’ effect of trademarks 101–2
- freedom of expression and information 80–81, 82, 86–8, 94–5, 103–5, 106, 110
- interference issues 73–5
- IP versus health debate 85–6
- market functionality of trademarks and hostage scenario 78–9
- misleading trademarks 77
- nudging lifestyle choices, effectiveness of 72, 108
- packaging and labelling, and advertising, distinction between 97–8
- packaging, removal of current mandatory indications of tar, nicotine and carbon monoxide levels 104
- plain packaging legislation (PPL) 74
- policy discretion 92, 106
- protection preliminaries 90–105
- right to health measurement 91–4
- sector-specificity in trademark law, lack of 77–8
- space appropriation and decreases in trademark manoeuvrability 74–5
- standardized packaging measures (SPM) 70–71, 73–4, 75, 78, 88–9, 90, 93, 99, 103, 104, 105–6, 107
- text warnings 70–71
- tobacco substitutes, lack of 75
- tobacco trademarks 99–101
- trademark expressionism 94–105
- trademark expressionism assessment 97–8
- trademark law concerns on health issues 76–9
- trademarks as property 88–90
- trademarks as protectable form of commercial expression 94–7
- unfair competition as complex and fluctuating 98–9
- very large pictorial warnings (VLPW) 70–71, 74, 75, 99, 103, 105–6, 107, 108
- Gangjee, D 264, 285, 286, 287, 291, 294, 301
- Garde, A 83, 84, 85, 92, 93
- Geiger, C 85–6, 253
- generic packaging *see* plain packaging

- generic products
 - generic descriptors and trademarks, EU Nutrition and Health Claims Regulation (NHCR) 153–4
 - generic drugs and patent protection 58
 - generic prescriptions, customer confusion between trade and generic brands 126–7, 131, 132, 136
 - generic prescriptions, UK 112
 - investment disputes, pharmaceutical patents 242, 243–4, 246–7, 249, 251
 - pay-for-delay agreements (patent dispute settlements) 8
- geographical indications
 - certification marks for public health 261
 - and TRIPS 165, 182–3
- geographical indications (GIs) and public health 283–304
 - asymmetrical information between producers and consumers, reduction of 288–9
 - consumer information availability 298–9
 - definition of GI, changing 292–6
 - ‘eat local’ movements 302–3
 - environmentally sustainable production, encouraging 299, 300
 - EU, ‘protected designation of origin’ (PDO) and ‘protected geographical indication’ (PGI) 295–6
 - free-riders, protection from 291–2
 - French appellations of origin 286–7, 293–5
 - GI protection issues 285–6
 - healthy product promotion 297–304
 - ‘higher quality’ products 284, 285
 - legal definition of GIs 285–6
 - Lisbon Agreement definition of appellations of origin 293–5
 - local and rural development promotion 289–91, 300–301
 - ‘locavore’ movements 302–3
 - marketing and market access tools, GIs as 285, 292–7
 - niche and high(er)-quality products 301
 - partially delocalized production model 296–7
 - production factors 271, 288–9, 292–7, 299, 303–4
 - production factors rather than *terroir*, increased focus on 292–7, 303–4
 - protection levels for GIs 291–2
 - quality control 299, 300–301
 - reputation factors 290, 291–2, 293, 294, 295
 - ‘slow food’ movement 302–3
 - terroir* as geographical origin and product quality 286–92
 - and TRIPS Agreement 287, 293, 294, 297
 - and TRIPS Agreement, and ‘essentially attributable to its geographical origin’ 294, 295, 296, 303–4
 - unhealthy products 297
 - value and consumer interest, capitalizing on 291–2
- Germany
 - ‘Anti-Aging Bier’ trademark 148
 - Hipp v Milupa* 145–6, 149–50
 - pharmaceutical trademarks 117
- Gervais, D 45, 47, 51, 56, 62, 65, 89, 171, 174, 176, 178, 181, 195, 253, 300
- Gibbons, L 96, 102
- Gibson, J 79
- Gigerenzer, G 37
- Giovannucci, D 285, 290, 299
- Giraud, G 288
- Glanz, K 28
- Global Partnership for Safe and Sustainable Agriculture (Global-GAP) 269
- global public–private partnership (PPP), certification marks for public health 257–8
- global value networks (GVNs) 257–8, 265–70
- Goebel, B 87

- Gorny, D 156, 158
 grandfather clause, transitional rules for
 existing trademarks and brand
 names, EU Nutrition and Health
 Claims Regulation (NHCR)
 147–50
 green patenting 310–11, 312, 320
 Greenawalt, K 104
 Griffiths, J 7, 86
 Griswold, A 268
 Grosse Ruse-Khan, H 85, 251, 331
 Grynberg, M 79
- Haber, B 140, 149
 Haeri, H 229, 230
 Hagen, A 142
 Handler, M 206
 Hanson, J 25, 271
 harmful products' promotion,
 trademark registration and rights
 56–63, 66–7
 Harnack, L 278
 Hass, J 280
 Hastings, G 16, 28, 227
 Hawthorne, K 279
- health
 certification marks *see* certification
 marks for public health
 claims, and nutrition *see* nutrition and
 health claims and EU trademark
 law
 and geographical indications (GIs)
 see geographical indications
 (GIs) and public health
 health-related goods, and investment
 disputes *see* investment disputes,
 pharmaceutical patents and
 health-related goods
 healthier food production *see* patents
 as tool to encourage production
 of healthier food
 and pharmaceuticals *see*
 pharmaceuticals
 and tobacco *see* tobacco headings
 see also food; nutrition
- Heavner, B 258, 265
 Helfer, L 87–8
 Hertz, A 239
- Hetu, J 260, 280
 HFSS (high in fat, salt and sugar) and
 alcohol, food packaging
 standardization requirements
 24–6, 29, 30
 Higgins, A 227
 Hobbes, T 35
 Hoffmann, A 226, 227
 Hohfeld, W 63, 64, 190–91, 192, 193,
 194, 197
 Holland, S 28
 Hong Kong–Australia BIT, tobacco
 packaging measures 220–22, 223,
 224–6, 228–30
 Hood, C 30
 hostage scenario, and market
 functionality of trademarks 78–9
 Howells, D 105
 Hudec, R 156
 Hughes, J 262, 285
 human rights, European Convention on
 Human Rights 83, 84, 92, 94–5,
 96, 97, 157, 158
 Hüttebräuker, A 148, 149
- ICSID Arbitral Tribunal Awards
 AES Summit Generation v Hungary
 227, 230, 231
 Alex Genin, Eastern Credit Ltd and
 AS Baltoil v Estonia 229, 231
 Alpha Projektholding v Ukraine 225,
 227
 Azurix Corporation v Argentina 225,
 226–7
 Biwater Gauff (Tanzania) v Tanzania
 225
 Cargill v Mexico 229
 CME Czech Republic v Czech
 Republic 225, 227
 Compañía del Desarrollo de Santa
 Elena v Costa Rica 225, 227
 Duke Energy v Ecuador 230
 EDF (Services) v Romania 230, 231
 Enron v Argentina 230
 Eureka v Poland 228
 Fireman's Fund Insurance Company
 v Mexico 225, 226, 229

- FTR Holdings SA (Switzerland), Philip Morris Products SA (Switzerland) and Abal Hermanos SA (Uruguay) v Oriental Republic of Uruguay* 214–15, 216–18, 221–3, 227, 228, 231
- GEA Group v Ukraine* 230
- Glamis Gold v USA* 229, 230
- Grand River Enterprises Six Nations v USA* 231
- Impregilo v Argentine Republic* 225, 230, 231
- International Thunderbird Gaming Corporation v Mexico* 229
- LG&E v Argentina* 225, 226, 229
- Loewen Group v United States* 249
- Marvin Feldman v Mexico* 229
- Metalclad Corp v Mexico* 227
- Parkerings-Compagniet v Lithuania* 225
- Pope & Talbot v Canada* 225, 228
- PSEG Global v Republic of Turkey* 230
- Saipem v the People's Republic of Bangladesh* 249
- SD Myers v Canada* 225, 229
- Sempra Energy v Argentina* 227
- Siemens AG v Argentina* 231
- Suez v Argentina* 227
- Técnicas Medioambientales Tecmed v Mexico* 225, 226, 227, 230
- Telenor Mobile Communications AS v the Republic of Hungary* 226, 229
- Tokios Tokeles v Ukraine* 225
- Total v Argentina* 230, 231
- Waste Management v Mexico* 228, 229
- Ikerd, J 303
- Incardona, R 105
- incentives and consumption control, plain packaging and other standardization requirements 40, 41
- India, plain packaging for tobacco products 89
- information
 availability, and geographical indications (GIs) 288–9, 298–9
 freedom of expression and information, trademarks, tobacco and health, EU 80–81, 82, 86–8, 94–5, 103–5, 106, 110
- intellectual property
 IP Act and right to use trademark, Sri Lanka *see* Sri Lanka, public health objectives through product labelling regulation, IP Act and right to use trademark and non-IP legislations 7–8
 regime conflicts, and standardization requirements 16–17, 41, 42
 regulatory requirements and IP rights 4–7
 rights, nutrition and health claims and EU trademark law 140–41, 148, 156–8
 versus health debate, fundamental rights and trademarks, tobacco and health, EU 85–6
see also patents; trademarks
- interference with investor's property, degree of, tobacco packaging measures 227–8
- interference issues, fundamental rights and trademarks, tobacco and health, EU 73–5
- International Center for Alcohol Policies 25
- International Code of Marketing of Breastmilk Substitutes 32, 44
- international investment *see* investment
- International Non-proprietary Name (INN) 115–17, 120, 121, 123–4, 130
see also trademarks in the pharmaceutical sector, EU
- investment
 bilateral investment and free-trade agreements 220–22, 223, 224–6, 228–30, 321
 international investment law and tobacco packaging measures *see* tobacco packaging measures

- affecting IP protection under international investment law
- investment disputes, pharmaceutical patents and health-related goods 233–54
 - Apotex v USA* 244–7, 249–50, 251
 - arbitral process in investment arbitration 236
 - arbitrator role 252–4
 - confidentiality in arbitral process 236
 - Eli Lilly v the Government of Canada* 243–4, 248, 250
 - fair and equitable treatment violation claims 247–50
 - foreign direct investment (FDI) and investment treaties 235
 - Free Trade agreements (FTAs) and TRIPS Agreement 252
 - generic products 242, 243–4, 246–7, 249, 251
 - international investment law and pharmaceutical patents 234–6
 - investment, notion of 237–9
 - investor-state arbitrations concerning pharmaceutical patents 237–51
 - Italy v Cuba* 237–8
 - NAFTA violations 245, 246–7, 248, 249–50
 - prudential jurisdictional doctrine or reasonable apprehension doctrine, reliance on 245
 - Servier v Poland* 238–9, 240–42, 247
 - Signa v Canada* 247–8
 - TRIPS Agreement obligations 244, 251–2, 253
 - Vienna Convention on the Law of Treaties (VCLT), interpretation rules 166, 169–70, 181, 182, 241, 253
 - see also* health; pharmaceuticals
- investment disputes, pharmaceutical patents and health-related goods, expropriation claims 239–47
 - compensation levels 247
 - compulsory licences 240
 - depriving owner of economic benefit 240, 241–3, 244, 245–6
 - direct or indirect 239–46, 249
 - non-discrimination element 242, 243, 250–51
 - parallel imports 240
 - proportionality issues 242–3
 - usefulness criteria 244
- Ireland, Public Health (Standardised Packaging of Tobacco) Act 1, 22, 23
- Italy
 - Competition Authority (ICA) and food labelling and advertising 151–2
 - Food Supplements Association (AIIPA) and ‘probiotic’ term use 153
 - Salini Costruttori and Italstrade v Kingdom of Morocco* 222
- Jacoby, J 105
- Japan, Patent Office accelerated examination programme 311
- Jones, T 80
- jurisdiction, prudential jurisdictional doctrine or reasonable apprehension doctrine, reliance on in investment disputes 245
- jurisdictional objections, tobacco packaging measures affecting IP protection under international investment law 221–4
- justifiable positive encumbrance on use of trademarks 66–8
- Justus, M 258, 265
- Kahneman, D 17
- Kappos, D 332
- Karunaratna, D 198
- Katz, A 259
- Kelsey, J 81
- Kenkel, D 29
- Kirby, K 40
- Knitter, M 117
- Kojo, D 284
- Kosssdorf, K 141
- Kramer, A 260, 280
- Kratzke, W 88
- Kruse, C 280
- Krystallis, A 101

- Krzeminska-Vamvaka, J 94, 95, 97
 Kühling, J 83, 84, 92
 Kur, A 45, 89, 296–7
 Kysar, D 25, 271
- labelling
 label ‘fatigue’ concerns 277–8
 packaging and labelling, and advertising, distinction between 97–8
 packaging and labelling factors, trademarks in the pharmaceutical sector, EU 123
 plain packaging *see* plain packaging regulation, Sri Lanka *see* Sri Lanka, public health objectives through product labelling regulation
see also advertising; brands; packaging; trademarks
- Lamy, P 306
 Landenburger, C 84, 91–2, 93
 Landes, W 259
 Lane, E 262, 312, 313
 Laurenza, E 7, 138–59
 Laustsen, R 78, 79
 Lefebvre, R 28
 legal cases *see* EFTA court; EU, legal cases; ICSID Arbitral Tribunal Awards; individual countries; London Court of International Arbitration; Permanent Court of Arbitration; World Health Organization; World Trade Organization (WTO) Dispute Settlement
- legal definition of geographical indications (GIs) 285–6
 legal and historical context, Sri Lanka, public health objectives through product labelling regulation 197–200
 legitimate interests of trademark owners 56–63, 66–7, 177–8, 179
 Lemley, M 88, 206, 259
 Leskien, D 324
 Liberman, Jonathan 3
 licences, compulsory, and expropriation of pharmaceutical patents 240
- Linder, N 279
 Lisbon Agreement definition of appellations of origin 293–5
 Lobstein, T 38
 local and rural development promotion, geographical indications (GIs) 289–91, 300–301
 ‘locavore’ movements 302–3
 London Court of International Arbitration, *EnCana Corporation v Republic of Ecuador* 228
 Lowenstein, G 25
 Lunsford, J 45
- McCarthy, J 59
 McCarthy, M 300
 McCarty, L 193
 McCombe, Justice 92, 94, 105
 McGeveran, W 88
 McGrady, B 24, 29, 49, 52, 53, 65, 214
 McLachlan, C 226
 mandatory disclosure 34, 40–41, 258, 269–70, 272
 Marie-Vivienne, D 289
 marijuana tracking through supply chain 267
 market functionality of trademarks and hostage scenario 78–9
 market manipulation concerns, certification marks for public health 259–60, 271–2, 275, 279–81
 marketing and market access tools, geographical indications as 285, 292–7
- Marsoof, A 48, 49, 61, 64, 89, 103, 113, 135, 169, 184–212, 228–9
 Marteau, T 28, 39
 Mattli, W 257
 medication errors review, Australia 126–7
 medicine information panel for non-prescriptive medicines, Australia 130, 132
 Meidinger, E 268
 Meisterernst, A 140, 149, 157
 Melchor, S 155
 Menapace, L 288, 289, 291, 301

- Mill, J 105
 Mills, O 315
 misleading trademarks 77, 123
 Mitchell, A 3, 16, 44, 51, 173, 213–32
 Montt, S 230
 Mooney, A 301
 morality, trademarks contrary to
 morality or public order 53–4
 Morcom, C 50
 Moschini, G 288, 291, 301
 Munro, C 94
 Munzer, S 288, 291
 Mylly, T 85
- NAFTA violations, investment disputes,
 pharmaceutical patents and
 health-related goods 245, 246–7,
 248, 249–50
 national treatment claims 168, 250–51
 ‘natural’ labels on food products 260
 negative rights, to prevent exploitation
 of brand 44–6, 50
 Nestle, M 276
 Netherlands
 *Bogstra v Co-operative Condensed
 Fabrik* 198–9
 Croos v De Soysa 199
 freedom of expression 83
 Kapadiya v Mohamad 198
 trademarks and Roman Dutch Law
 [RDL] 198–200
 neutrality principle paradox, patents as
 tool to encourage production of
 healthier food 325–6
 Newcombe, A 226
 NGO involvement, certification marks
 for public health 268–9
 niche and high(er)-quality products, and
 geographical indications 301
 non-communicable diseases increase,
 patents as tool to encourage
 production of healthier food
 305–6, 307–8
 non-compliance with food law regime
 effects, EU Nutrition and Health
 Claims Regulation (NHCR) 143
 non-discrimination element, investment
 disputes, pharmaceutical patents
 and health-related goods 242, 243,
 250–51
 non-prescriptive medicines, medicine
 information panel, Australia 130,
 132
 non-traditional pharmaceutical
 trademarks 118
 non-word trademarks 163–5
 Northern, G 280
 Norway, freedom of expression 83
 notice-based forms of regulation
 (mandatory disclosure) 258,
 269–70, 272
 nudge concept
 behavioural sciences 30–32, 35–6,
 37–9, 40, 41–2
 certification marks for public health
 271–4
 lifestyle choices, effectiveness of 72,
 108
 nutrition
 bilateral investment and free-trade
 agreements and protection of
 public health and nutrition 321
 nutrient profiles 139–40, 328–9
 see also food; health
 nutrition and health claims and EU
 trademark law 138–59
 Charter of Fundamental Rights of the
 EU (CFREU) and freedom of
 expression 157–8
 commercial communication as
 trademark 144, 148–9, 157–8
 European Food Safety Authority
 (EFSA) 145, 153, 155
 freedom of expression and European
 Convention for the Protection of
 Human Rights and Fundamental
 Freedoms (ECHR) 157–8
 IP rights 140–41, 148, 158
 nutrient profiles 139–40
 ‘OMEGA 3’ figurative trademark 144
 Slim Fast trademark 152–3
 trademark inclusion issues 140
 nutrition and health claims and EU
 trademark law, Nutrition and
 Health Claims Regulation
 (NHCR) 138–58

- brand-specific nutrition and health claims 154–5
- coupling principle 141
- Flexibility Guidance 154–5
- food operators' trademarks, use of 143–4
- generic descriptors and trademarks 153–4
- health claims concept 146–7
- international IP provisions and fundamental rights, compliance with 156–8
- and national advertising supervision bodies 150–52
- non-compliance with food law regime effects 143
- 'probiotic', use of term 145–6, 153–4
- trademarks at risk 152–3
- trademarks as health claims 144–6
- and traditional trademark law 142–6
- transitional rules for existing trademarks and brand names ('grandfather' clause) 147–50

- obesity increase, patents as tool to encourage production of healthier food 305–6, 307–8
- Obolevich, V 74, 79
- O'Connor, B 285
- Oliver, P 95
- Ollberding, N 278
- Olynk, N 269
- 'OMEGA 3' figurative trademark 144
- 'organic' labelling 260, 264, 267, 274–5, 279–81
- Osseweijer, P 274
- Oude Ophuis, P 301

- packaging
 - and advertising, distinction between 97–8
 - plain *see* plain packaging
 - removal of current mandatory indications of tar, nicotine and carbon monoxide levels 104
 - trademarks in the pharmaceutical sector, EU 123
 - see also* labelling

- parallel imports, investment disputes, pharmaceutical patents and health-related goods 240
- Paris Convention
 - and patents 326–7
 - plain packaging of tobacco products, Australia 168, 169, 170–71, 177–8, 180–81, 182
 - trademark law protection 77
 - trademark registration and rights 47–9, 51, 52–5, 56–7, 65
 - see also* World Trade Organization (WTO) TRIPS Agreement
- partially delocalized production model, geographical indications (GIs) and public health 296–7
- Paster, B 206
- patents
 - pharmaceutical patents and investment disputes *see* investment disputes, pharmaceutical patents and health-related goods
 - see also* intellectual property; trademarks
- patents as tool to encourage production of healthier food 305–32
 - bilateral investment and free-trade agreements and protection of public health and nutrition 321
 - costs/benefits analysis criterion 316, 326, 329
 - differentiation and refusal of neutrality principle 322–4
 - discrimination versus differentiation 319–21
 - European Patent Convention (EPC) and TRIPS, patents contrary to *ordre public* or morality 314, 317, 323, 326–7
 - expert involvement 328
 - fast-track procedures for patent applications 310–13, 317, 319, 331–2
 - fee exemption suggestion 313, 329
 - food-related patents 307–8
 - green patenting 310–11, 312, 320

- international patent No WO 2013162802 A1, fat particle compositions 308
- neutrality principle paradox 325–6
- nutrient profiling model 328–9
- obesity and non-communicable diseases, increase in 305–6, 307–8
- Patent Cooperation Treaty (PCT) and fast-track procedures 312–13
- patent regime amendments to incentivize production of healthy foodstuffs 309–18
- protection term extension 317–18
- socially useful technologies, use of 310, 312, 319–20
- and TRIPS Agreement 314, 317, 318, 319, 321, 328
- TRIPS anti-discrimination rule 318
- TRIPS and plant variety rights protection 324
- unhealthy food, proposal for exclusion from patentability 313–17, 325–7
- US Patent No 5260087, fat and egg yolk substitute 307
- US patent No 6485775, fat substitute 308
- US patent No 8647696, low fat food containing gas bubbles 307–8
- Patton, A 311
- pay-for-delay agreements (patent dispute settlements), generic products 8
- Peritz, Rudolph 8
- Permanent Court of Arbitration
 - Chorzów Factory Case (Germany v Poland)* 240
 - German Interests in Polish Upper Silesia* 239–40
 - Philip Morris Asia Ltd (Hong Kong) v Australia* 213, 217, 218, 223–5, 228, 230–31
 - Saluka Investments v Czech Republic* 226, 230
- Peru, Act to Promote Healthy Eating among Children and Adolescents 26–7
- Pettman, S 140
- pharmaceuticals
 - behavioural sciences, plain packaging and other standardization requirements 27–8
 - investment disputes *see* investment disputes, pharmaceutical patents and health-related goods
 - trademarks *see* trademarks in the pharmaceutical sector, EU *see also* health
- Phillips, J 76, 77, 78, 85, 300
- pictorial health warnings on tobacco packs, introduction of, Sri Lanka 185–202, 207–8
- Pildes, R 34, 41
- Pires de Carvalho, N 65, 66
- plain packaging
 - and behavioural sciences *see* behavioural sciences, plain packaging and other standardization requirements
 - challenges, Sri Lanka 205–11
 - generic packaging history 21–2
 - and international investment law 215–16, 217, 218
 - legislation, fundamental rights and trademarks, tobacco and health, EU 74
 - tobacco products, trademark registration and rights 60–61 *see also* packaging
- plain packaging of tobacco products, Australia, and WTO TRIPS challenge 163–83
- approaches to interpretation 166–7, 169–70, 181, 182
- Australian measures and non-word trademarks 163–5
- claims concerning trademarks and geographical indications 165
- geographical indications (Articles 22.2 and 24) 182–3
- government restrictions on the use of trademarks (Article 19) 179–80
- individual claims 167–74

- intellectual property conventions (Article 2.1) 168
- national treatment claim (Article 3) 168
- Paris Convention 168, 169, 170–71, 177–8, 180–81, 182
- protectable subject matter and definition of trademark (Article 15.1) 168–9
- protectable subject matter and registration of trademark (Article 15.1) 169
- rights conferred and prevention of particular uses of registered trademark that is well known (Article 16.3) 170–71
- rights conferred and trademark protection (Article 16.1) 169–70, 177, 178
- unjustifiably encumbered by special requirements (Article 20) 171–82
- unjustifiably encumbered by special requirements (Article 20), duelling contexts 176–82
- unjustifiably encumbered by special requirements (Article 20), and legitimate interests of trademark owners (and Article 17) 177–8, 179
- unjustifiably encumbered by special requirements (Article 20), meaning of 174–6
- unjustifiably encumbered by special requirements (Article 20), relationship between trademark owners and governments acting as regulators 178–9
- unjustifiably encumbered by special requirements (Article 20), right to regulate for public health and ‘spirit of use’ international trademark law argument 180–81
- plant varieties protection and TRIPS 324
- Plomer, A 315
- political acceptability, plain packaging and other standardization requirements 34–5
- Pollay, R 101
- Poncibo, C 105
- population sub-groups, differing effects of certification marks on 278–9
- positive rights, trademark registration 47–63
- Posner, R 78, 259
- Pottage, A 17
- Powys Whyte, K 38
- prescription products, and trademarks 115
- Preston Smith, J 260
- price factors in consumer choice 277
- prior exclusive rights of a third party, trademark registration 54
- private non-profit organizations involvement, certification marks for public health 268–9
- privilege of using trademark 63–4
- ‘probiotic’, use of term, EU Nutrition and Health Claims Regulation (NHCR) 145–6, 153–4
- product labelling *see* labelling
- production factors, geographical indications (GIs) and public health 271, 288–9, 292–7, 299, 303–4
- property, trademarks as 88–90
- proportionality issues
 - investment disputes, pharmaceutical patents and health-related goods 242–3
 - public interest and tobacco packaging measures 226–7
- protectable subject matter and definition of trademark 168–9
- protection levels for geographical indications 291–2
- protection term extension, patents as tool to encourage production of healthier food 317–18
- prudential jurisdictional doctrine or reasonable apprehension doctrine, reliance on, investment disputes, pharmaceutical patents and health-related goods 245

- public health *see* health
- public institution initiatives,
certification marks for public
health 266–7
- public interest
- legislative measures for restricting
trademark use 48–9
 - population sub-groups, differing
effects of certification marks on
278–9
 - proportionality measures, tobacco
packaging measures under
international investment law
226–7
 - socially useful technologies, use of
310, 312, 319–20
- public order, trademarks contrary to
morality or public order 53–4
- public–private partnership (PPP),
certification marks for public
health 257–8
- quality
- control, geographical indications
299, 300–301
 - credence attributes, certification
marks for public health 262,
269–70
 - ‘higher quality’ products,
geographical indications 284,
285
 - terroir* as geographical origin and
product quality 286–92
- Rafter, M 159
- Rahmatian, A 88
- Ramsey, L 88
- Randall, M 83
- Rangnekar, D 289–90
- Ratione Temporis Argument, tobacco
packaging measures under
international investment law 223
- Ratnapala, S 193
- Raustiala, K 288, 291
- reasonable apprehension doctrine,
reliance on, investment disputes,
pharmaceutical patents and
health-related goods 245
- Rebonato, R 18
- refusal of neutrality principle, patents as
tool to encourage production of
healthier food 322–4
- registration
- and brand protection 112–13, 114–15
 - tablet or capsule shapes and flavours
118
 - trademarks *see* trademark registration
and rights
- ‘regulatory chill’ effect 41
- regulatory clearance of pharmaceutical
names 120–21
- regulatory requirements and IP rights
4–7
- Reinisch, A 226, 227
- removable trademarks after purchase,
Sri Lanka 209–11
- renewal of trademarks containing
banned descriptors 51–2, 60
- reputation factors, geographical
indications 290, 291–2, 293, 294,
295
- revocation argument, trademark
registration and rights 55–6
- Ricketson, Sam 3
- Ricolfi, M 285, 321–2
- right to health measurement,
fundamental rights and
trademarks, tobacco and health,
EU 91–4
- rights
- conferred and prevention of
particular uses of registered
trademark that is well known
170–71
 - EU Charter of Fundamental Rights 6,
71, 82–3, 84, 91–2, 94–5, 157–8
 - free speech rights 102–3, 205–6
 - freedom of choice 35–6
 - freedom of expression 80–81, 82,
86–8, 94–5, 103–5, 106, 110,
157–8
 - fundamental *see* fundamental rights
- Ritzert, M 289, 291
- Roberto, C 266, 276, 278
- Röhr, A 301

- Roman Dutch Law (RDL), Sri Lanka, public health objectives through product labelling regulation 198–200
- Rotstein, F 265
- Rubino, A 284
- Sakulin, W 88
- Salacuse, J 226
- Salas, B 153
- Salguero, M 303
- Salini* test, tobacco packaging measures and international investment law 222
- Samaraweera, K 203
- Scassa, T 87
- Schechter, F 88, 206
- Schifferstein, H 301
- Schneider, C 40, 41, 271, 275
- Schovsbo, J 88
- Schreuer, C 230
- Schuldt, J 279
- Schwarz, N 279
- Scott, C 269
- Sebrié, E 219
- sector-specificity in trademark law, lack of 77–8
- self-expression, and cultural currency effect of trademarks 101–2
- Selinger, E 37–8
- Senftleben, M 86
- Shanahan, D 206
- Sherman, B 318, 322, 325, 329, 331
- Shiffman, S 100
- Shiner, R 94
- Sibony, A-L 35, 38
- signalling, trademark's signalling function 259, 275
- Sinclair, I 253
- Skoblikov, L 155
- Sleenhoff, S 274
- Slim Fast trademark 152–3
- 'slow food' movement 302–3
- Smith, H 192
- Snowdon, C 87
- socially useful technologies, use of 310, 312, 319–20
see also public interest
- Sommer, T 315
- Sornarajah, M 236
- South Africa
Foodstuffs, Cosmetics and Disinfectants Act 32
IP rights 199–200
space appropriation and decreases in trademark manoeuvrability 74–5
- Spence, M 88, 95–6, 102
- Spina, A 18, 104
- 'spirit of use', international trademark law 180–81
- Sri Lanka, legal cases
Ceylon Bank Employees Union v Commissioner of Labour 203
Ceylon Tobacco Company v Hon Maithripala Sirisena, Minister of Health 103, 186–7, 188, 200, 202, 204, 208
Joseph Perera v the Attorney General 207
Karunathilaka v Dayananda Dissanayake 206
Leelananda v Earnest de Silva 188
Sunila Abseysekera v Ariya Rubasinghe 207, 209
- Sri Lanka, public health objectives through product labelling regulation 184–212
advertising and the use of trademarks on products, distinction between 188–9
Agrarian Development Ordinance 201
Ceylon Tobacco Company (CTC) challenge to legality of Tobacco Regulations 186–7, 188 and free speech rights 205–6 and fundamental rights 206–9
National Authority on Tobacco and Alcohol (NATA) Act 184–5, 186–7, 188–9, 202
National Authority on Tobacco and Alcohol (NATA) Act, 2015 Amendment 203–5
National Authority on Tobacco and Alcohol (NATA) Act, 2015

- Amendment, Supreme Court determination 204–5, 207–8
- pictorial health warnings on tobacco packs, dimensions of 187–8, 203–4
- pictorial health warnings on tobacco packs, introduction of 185–202, 207–8
- plain packaging challenges 205–11
- plain packaging challenges, and trade restrictions 206–7
- removable trademarks after purchase 209–11
- Tobacco Products (Labelling and Packaging) Regulations 185–7, 202
- Trade Marks Act 198
- trademark law and consumer protection 206, 210–11
- Urban Development Authority 201–2 and WHO Framework Convention on Tobacco Control (FCTC) 187
- Sri Lanka, public health objectives through product labelling regulation, IP Act and right to use trademark
- Australian Tobacco Plain Packaging Act comparison 189–95
- exclusive rights 195–6
- interpretation of 188, 189–201, 205
- legal and historical context 197–200 and Roman Dutch Law (RDL) 198–200
- trademark rights as absolute 201–2
- TRIPS Agreement and trademark rights (Article 16) and right to exclude unauthorized third-party use 195–7, 198
- standardization requirements, and behavioural sciences *see* behavioural sciences, plain packaging and other standardization requirements
- standardized packaging measures (SPM), fundamental rights and trademarks, tobacco and health, EU 70–71, 73–4, 75, 78, 88–9, 90, 93, 99, 103, 104, 105–6, 107
- Starling, S 152
- Staver, A 267
- Sterckx, S 315
- Stern, B 240
- Stern, S 55–6
- Stone, A 80–81
- Stout, M 318
- Strom, S 273
- Studdert, L 130
- substantive claims, tobacco packaging measures and international investment law 224–31
- Sunstein, C 17, 30, 36, 38, 39, 108, 270, 271, 272, 273
- supply chain management 267
- sustainability, environmentally sustainable production, encouraging 299, 300
- Switzerland–Uruguay BIT, tobacco packaging measures 220–22, 223, 224–6, 228–30
- Tallent, K 230
- technologies, socially useful technologies, use of 310, 312, 319–20
- terroir see under* geographical indications
- Thailand, alcohol products 24–5
- Thaler, R 17, 30, 36, 108, 270, 271, 272, 273
- Thambisetty, S 315, 326, 330
- Thorndike, A 277
- tobacco
 - behavioural sciences, plain packaging and other standardization requirements 29, 32–3, 35, 40
 - and health *see* fundamental rights and trademarks, tobacco and health, EU
 - plain packaging, Australia *see* plain packaging of tobacco products, Australia, and WTO challenge
 - plain packaging and tobacco control strategies 20–21
 - plain packaging, trademark registration and rights 60–61

- substitutes, lack of 75
- tobacco packaging measures affecting
 - IP protection under international investment law 213–32
- Australia, plain packaging measures 215–16, 217, 218
- expropriation clauses 224–9
- fair and equitable treatment (FET) 226, 229–31
- interference with the investor's property, degree of 227–8
- investments under Switzerland–Uruguay and Hong Kong–Australia BITs 220–22, 223, 224–6, 228–30
- jurisdictional objections 221–4
- Permanent Court of Arbitration, *Philip Morris Asia Ltd (Hong Kong) v Australia* 213, 217, 218, 223–5, 228, 230–31
- public interest proportionality measures 226–7
- Ratione Temporis Argument 223
- Salini* test 222
- substantive claims 224–31
- TRIPS Agreement trademark rights (Article 16.1) 228
- Uruguay tobacco packaging and labelling 214–15, 216–18
- Torremans, P 86, 87, 315
- tracermark suggestion, certification marks for public health 281
- trade dress protection, plain packaging and other standardization requirements 15–16
- trade restrictions, Sri Lanka, public health objectives through product labelling regulation 206–7
- trademark(s)
 - and advertising 58–61, 62, 63, 188–9
 - claims concerning trademarks and geographical indications 165
 - commercial communication as 94–7, 144, 148–9, 157–8
 - contrary to morality or public order 53–4
 - and exaggerated marketing claims 259–60
 - and fundamental rights *see* fundamental rights and trademarks, tobacco and health, EU
 - international trademark law 47–8, 180–81
 - law and certification marks 259–65
 - legitimate interests, plain packaging of tobacco products, Australia, and WTO TRIPS challenge 177–8, 179
 - legitimate interests of trademark owners 56–63, 66–7, 177–8, 179
 - misleading trademarks 77, 123
 - plain packaging of tobacco products, Australia, and WTO TRIPS challenge 170–71, 178–80
 - rights, Sri Lanka *see* Sri Lanka, public health objectives through product labelling regulation, IP Act and right to use trademark
 - signalling function, certification marks for public health 259, 275
 - see also* advertising; brands; intellectual property; labelling; patents
- trademark registration and rights 43–68
 - advertising function of trademarks 58–61, 62, 63
 - alleged purposive interpretation of international trademark law provisions 47–8
 - distinguishing products from competitors, concerns about 59–60
 - domestic trademark laws, interpretation of 49–50
 - economic value of registrations 51, 62
 - generic drugs and patent protection 58
 - harmfulness of product and IP analysis 62–3
 - justifiable positive encumbrance on use of trademarks 66–8
 - legislative measures for restricting use in public interest 48–9

- legitimate interests of trademark owners and promotion of harmful products 56–63, 66–7
- negative rights, to prevent exploitation of brand 44–6, 50
- plain packaging of tobacco products 60–61
- positive rights 47–63
- privilege of using trademark 63–4
- registration of a sign which violates prior exclusive rights of a third party 54
- registration versus use 50–55, 57–8, 62
- renewal of trademarks containing banned descriptors 51–2, 60
- revocation argument 55–6
- trademarks contrary to morality or public order 53–4
- TRIPS Agreement, Article 20 64–8
- TRIPS Agreement and Paris Convention, alleged spirit of 47–9, 51, 52–5, 56–7, 65
- unjustifiable positive encumbrance on use of trademarks 65–6
- word trademarks 60–61, 67–8
- trademarks in the pharmaceutical sector, EU 112–37
 - active pharmaceutical ingredients (APIs) 115, 126–32
 - compound medicines 127
 - confusion likelihood assessment 119–20, 123, 124, 126–7, 130
 - consumer knowledge and awareness 115, 117, 118, 119–20, 126–7, 131–2, 133
 - descriptive names 116, 117
 - distinctiveness, lack of sufficient 115–18
 - European Medicine Agency (EMA) 113, 120–21
 - European Medicine Agency (EMA) approval process (Name Review Group (NRG)) 122–5
 - generic prescriptions, customer confusion between trade and generic brands 126–7, 131, 132, 136
 - International Non-proprietary Name (INN) 115–17, 120, 121, 123–4, 130
 - misleading pharmaceutical qualities 123
 - non-traditional pharmaceutical trademarks 118
 - Office of Harmonization in the Internal Market (OHIM) (Trade Marks and Designs) 113, 114, 117, 120
 - packaging and labelling factors 123
 - pharmacologically-related substances and common stem 116
 - prescription products 115
 - regime differences 124–5
 - registration and brand protection 112–13, 114–15
 - regulatory clearance of pharmaceutical names 120–21
 - statutory framework 121
 - tablet or capsule shapes and flavours, registration of 118
 - see also* pharmaceuticals
 - trademarks in the pharmaceutical sector, EU, Australian regulatory requirements comparison 125–30
 - active ingredient, prominence and placement 128–32
 - bans on brand extension medicines (umbrella brands) 133–5
 - consumer knowledge and awareness 126–7, 131–2, 133
 - draft Therapeutic Goods Order 128–30
 - impact on pharmaceutical brands 130–32
 - medication errors review 126–7
 - medicine information panel for non-prescriptive medicines 130, 132
 - Therapeutic Goods Administration (TGA) 125–32
- Tran, S 311, 313, 324
- Tregear, A 288
- Tritton, G 316
- Turkey, alcohol products 25

- Tushnet, R 5, 91
- UK
- Advertising Standards Authority (ASA) and food labelling and advertising 150–51
 - Food Standards Agency, nutrient profiling model 328–9
 - Intellectual Property Office (IPO) and pharmaceutical trademarks 116–17
 - Medicines and Healthcare Regulatory Agency (MHRA) 122, 134
 - nutrition and health claims and trademarks at risk 152–3
 - Patent Office prioritized examination system 310
 - Standardised Packaging of Tobacco Products Regulations 1, 22, 23, 56, 83
 - trademark law and freedom of expression 86
 - trademark regulations 45–6, 48
 - umbrella branding in pharmaceuticals 134
- UK, legal cases
- Anisminic v Foreign Compensation Commission* 203
 - British American Tobacco v Department of Health* 3, 6, 17, 45–6, 48, 60–61, 67, 98, 106, 169, 170, 200–201
 - J Bolliger v Costa Brava Wine* 287
 - London Borough of Hackney v Cedar Trading* 76
 - R (on the application of British American Tobacco UK Ltd) v Secretary of State for Health* 136
 - R (on the application of Lumsdon) v Legal Services Board* 99
 - R (on the application of Philip Morris Brands Sarl) v Secretary of State for Health* 136
 - Smith-Kline & French Laboratories v Sterling-Winthrop Group* 118
 - Tobacco Packaging* 72, 82, 93, 102, 108, 110
 - umbrella brands (bans on brand extension medicines) 133–5
 - unhealthy food, proposal for exclusion from patentability 313–17, 325–7
 - unhealthy products, geographical indications (GIs) and public health 297
 - unjustifiable positive encumbrance on use of trademarks 65–6
 - unjustifiably encumbered by special requirements *see under* plain packaging of tobacco products, Australia, and WTO TRIPS challenge
- Uruguay
- legislation on misleading or deceptive tobacco packaging 23–4
 - Philip Morris v Uruguay* 23–4
 - Switzerland–Uruguay BIT, tobacco packaging measures 220–22, 223, 224–6, 228–30
 - tobacco packaging and labelling 214–15, 216–18
- US
- Affordable Health Care Act 266
 - certification marks as geographical indications 261
 - certification marks for public health *see* certification marks for public health
 - Federal Food, Drug and Cosmetic Act 244–5
 - freedom of expression 103–4
 - LEED mark and Green Building Council 262
 - ‘natural’ labels on food products 260
 - Organic Foods Production Act 267
 - Patent Office, patentability exclusion for inventions considered immoral 314–15
 - Patent Office prioritized examination system 310, 311
 - patents to encourage production of healthier food 307–8
 - sugary beverage products labelling, California 26
 - trademark law 78–9, 206

- Washington State Liquor Cannabis (formerly Control) Board (WSLCB) 267
- US, legal cases
Class Action Compl, Howerton v Cargill 260
Class Action Compl and Jury Demand, Martin v Cargill 260
Diamond v Chakrabarty 330
Hanover Star Milling Co v Metcalf 206
Lowell v Lewis 315
R J Reynolds Tobacco Co v Food and Drug Admin 104
Swiss Watch International v Federation of the Swiss Watch Industry 263–4
Virginia State Board of Pharmacy v Virginia Citizens Consumer Council 95, 103–4
- usefulness criteria, pharmaceutical patents and health-related goods 244
- Vadi, V 233–54
- value
 and consumer interest, geographical indications capitalizing on 291–2
 global value networks (GVNs) 257–8, 265–70
- Van den Brink, M 96
- Van der Merwe, C 200, 201
- Van Harten, G 236
- Vandebergh, M 31
- Vandavelde, K 231
- Vaver, D 87, 266
- Verhoestraete, F 143, 144
- Verpeaux, M 83
- very large pictorial warnings (VLPW) 70–71, 74, 75, 99, 103, 105–6, 107, 108
- Vienna Convention on the Law of Treaties (VCLT), interpretation rules 166, 169–70, 181, 182, 241, 253
- Voight, J 302
- Voon, T 81, 87, 173, 218, 219, 298
- Wakefield, M 41–2
- Wansink, B 277, 278
- Watson, J 105
- ‘wear-off’ effect, risk of 37
- Weatherill, S 105
- Wells, A 330
- Williams, C 301
- Williams, E 284
- WIPO Intellectual Property Handbook* 196–7
- Woods, L 97
- word trademarks 60–61, 67–8
- World Health Organization (WHO)
 Framework Convention on Tobacco Control (FCTC) 1, 21, 23, 79–80, 97–8, 99–100, 106, 164, 187, 215, 216, 222–3, 226–7
 Guidelines on Marketing to Children 30
Methanex Corporation v USA 223
 pharmacological name approval and International Non-proprietary Name (INN) 116, 117, 122, 124
 Punta del Este Declaration on measures to protect public health 226
 very large pictorial warnings (VLPW) 74
- World Trade Organization (WTO)
 Dispute Settlement
Brazil–Tyres 172, 174
Canada – Pharmaceutical Patents 57, 58, 320–21
Canada – Term of Patent Protection 319
DS434 ‘Australia – Certain Measures Concerning Trademarks and Other Plain Packaging Requirements Applicable to Tobacco Products and Packaging 89, 218–19
EC – Trademarks and Geographical Indications 46, 48, 56–7, 62, 68, 196, 197, 200–201, 228
EC–Hormones 166
EC–Seals 172, 174
US – Section 211 Appropriation Acts 55

- US–Continued Zeroing* 167
US–Shrimp 167
 World Trade Organization (WTO)
 TRIPS Agreement
 Doha Declaration on Public Health
 179–80
 and Free Trade agreements (FTAs)
 252
 geographical indications 287, 293,
 294, 297
 geographical indications, ‘essentially
 attributable to its geographical
 origin’ 294, 295, 296, 303–4
 obligations, investment disputes,
 pharmaceutical patents and
 health-related goods 244, 251–2,
 253
 patent rights, permitted exceptions to
 (Article 30) 57
 patents contrary to *ordre public* or
 morality 314, 317, 323, 326–7
 patents as tool to encourage
 production of healthier food 314,
 317, 318, 319, 321, 324, 328
 plain packaging of tobacco products,
 Australia *see* plain packaging of
 tobacco products, Australia, and
 WTO TRIPS challenge
 plant variety rights protection 324
 trademark holders, legitimate
 interests of (Article 17) 57
 trademark registration and rights
 (Article 20) 64–8
 trademark registration and use
 (Article 15) 51, 52, 77
 trademark revocation (Article 19) 56
 trademark rights and right to exclude
 unauthorized third-party use
 (Article 16) 195–7, 198
 trademark rights, tobacco packaging
 measures and international
 investment law (Article 16.1)
 228
 trademarks and exclusive rights
 (Article 16) 45–6
 see also Paris Convention
- Yannaca-Small, K 227
 Yeung, K 34
 Yoghurt and Live Fermented Milks
 Association (YLFA), ‘probiotic’
 term use 153
 Yong, H-H 42
 Yu, P 88
- Zahaf, M 303
 Zapata, A 289, 300
 Zimmermann, D 95

